PMID

Data

Article Title

Organization

Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach.

Zhengzhou University

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO).

Zhengzhou University

Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: success and challenges.

Zhengzhou University

Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.

Zhengzhou University

Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.

Zhengzhou University

Synthesis and biological evaluation of (R)-N-(diarylmethylthio/sulfinyl)ethyl/propyl-piperidine-3-carboxylic acid hydrochlorides as novel GABA uptake inhibitors.

Zhengzhou University

Discovery and synthesis of novel luteolin derivatives as DAT agonists.

Zhengzhou University

Application and synthesis of thiazole ring in clinically approved drugs.

Zhengzhou University

Design, synthesis and biological evaluation of nitric oxide-releasing 5-cyano-6-phenyl-2, 4-disubstituted pyrimidine derivatives.

Zhengzhou University

Synthesis of andrographolide derivatives: a new family of alpha-glucosidase inhibitors.

Zhengzhou University

Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers.

Zhengzhou University

Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway.

Zhengzhou University

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.

Zhengzhou University

Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.

Zhengzhou University

Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice.

Zhengzhou University

Annual review of KRAS inhibitors in 2022.

Zhengzhou University

Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.

Zhengzhou University

Discovery of Novel 1,3-Diphenylpyrazine Derivatives as Potent S-Phase Kinase-Associated Protein 2 (Skp2) Inhibitors for the Treatment of Cancer.

Zhengzhou University

Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications.

Zhengzhou University

Bis-chalcone polyphenols with potential preventive and therapeutic effects on PD: Design, synthesis and in vitro disaggregation activity against α-synuclein oligomers and fibrils.

Zhengzhou University

Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy.

Zhengzhou University

4-Arylidene curcumin derivatives in vitro inhibit α-Synuclein aggregation and disaggregate the preformed fibril.

Zhengzhou University

Target discovery of bioactive natural products with native-compound-coupled CNBr-activated Sepharose 4B beads (NCCB): Applications, mechanisms and outlooks.

Zhengzhou University

Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma.

Zhengzhou University

Structural and Functional Landscape of FAD-Dependent Histone Lysine Demethylases for New Drug Discovery.

Zhengzhou University

Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.

Zhengzhou University

Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.

Zhengzhou University

Semisynthesis, biological activities, and mechanism studies of Mannich base analogues of magnolol/honokiol as potential α-glucosidase inhibitors.

Zhengzhou University

Andrographolide and its derivatives: Current achievements and future perspectives.

Zhengzhou University

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.

Zhengzhou University

Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.

Zhengzhou University

Chemical probe of AHL modulators on quorum sensing in Gram-Negative Bacteria and as antiproliferative agents: A review.

Zhengzhou University

Targeting histone demethylase KDM5B for cancer treatment.

Zhengzhou University

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.

Zhengzhou University

Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.

Zhengzhou University

Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues.

Zhengzhou University

FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.

Zhengzhou University

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.

Zhengzhou University

Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities.

Zhengzhou University

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.

Zhengzhou University

Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.

Zhengzhou University

Hybrids of polyphenolic acids and xanthone, the potential preventive and therapeutic effects on PD: Design, synthesis, in vitro anti-aggregation of α-synuclein, and disaggregation against the existed α-synuclein oligomer and fibril.

Zhengzhou University

Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

Zhengzhou University

Discovery of Novel Pyrazole-Based KDM5B Inhibitor

Zhengzhou University

A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.

Zhengzhou University

The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.

Zhengzhou University

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.

Zhengzhou University

Discovery of the Triazolo[1,5-

Zhengzhou University

Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity.

Zhengzhou University

Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects.

Zhengzhou University

Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors.

Zhengzhou University

Discovery of 1,2,4-triazine dithiocarbamate derivatives as NEDDylation agonists to inhibit gastric cancers.

Zhengzhou University

Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.

Zhengzhou University

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction.

Zhengzhou University

Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.

Zhengzhou University

Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.

Zhengzhou University

Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR

Zhengzhou University

Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.

Zhengzhou University

Current development of CBP/p300 inhibitors in the last decade.

Zhengzhou University

New drug approvals for 2019: Synthesis and clinical applications.

Zhengzhou University

Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors.

Zhengzhou University

Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).

Zhengzhou University

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-

Zhengzhou University

Novel tertiary sulfonamide derivatives containing benzimidazole moiety as potent anti-gastric cancer agents: Design, synthesis and SAR studies.

Zhengzhou University

Amide derivatives of Gallic acid: Design, synthesis and evaluation of inhibitory activities against in vitro α-synuclein aggregation.

Zhengzhou University

Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.

Zhengzhou University

Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.

Zhengzhou University

Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.

Zhengzhou University

Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.

Zhengzhou University

Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.

Zhengzhou University

Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation.

Zhengzhou University

Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors.

Zhengzhou University

Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells.

Zhengzhou University

NOTA analogue: A first dithiocarbamate inhibitor of metallo-β-lactamases.

Zhengzhou University

Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.

Zhengzhou University

Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR).

Zhengzhou University

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance.

Zhengzhou University

Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.

Zhengzhou University

3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.

Zhengzhou University